In fact, biodistribution data from clinical trials showed that pretargeting with BC4 results in about 25 times more radioactivity on the tumour than on non-tumour tissues (Paganelli et al, 1999), while no biodistribution data are available for BC2. This evidence concerns the gene CHMP2A and neoplasm.